NEW YORK (GenomeWeb) – LifeCodexx and Elucigene Diagnostics said today that they have partnered to make LifeCodexx's noninvasive prenatal screening test, PrenaTest, available to patients in the UK and Ireland.
Konstanz, Germany based-LifeCodexx launched PrenaTest based on technology it licensed from Sequenom in 2012 and has made the test available throughout Europe. Elucigene Diagnostics, based in Manchester, UK, is a developer and distributor of prenatal and human genetic diagnostics.
Mark Street-Docherty, commercial manager of Elucigene Diagnostics, said in a statement that offering LifeCodexx's PrenaTest "complements our continued support for prenatal testing accuracy."
PrenaTest is now available in more than 40 countries throughout Europe and the Middle East, Michael Lutz, CEO of LifeCodexx, noted in a statement.
Earlier this year, LifeCodexx inked deals with partner labs in Germany and Switzerland for the test.